European drug regulators said today that cancer patients with a “reasonably long life-expectancy” should get blood transfusions rather than take anemia drugs. A statement from the European Medicines Agency (EMEA) is online here.
Anemia is a common side effect of chemotherapy, and anemia drugs such as Amgen’s Aranesp and Johnson & Johnson’s Procrit (sold in Europe [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment